Analysis of Anti-psychotic Drug Penfluridol in Human Plasma by HPLC and MS/MS

Authors

  • Arnav Walia Associate Research trainee, Synergen Bio Pvt. Ltd., Pune, Maharashtra, India
  • Mansingh Rajput Head Bioanalytical Research, Synergen Bio Pvt. Ltd., Pune, Maharashtra, India
  • Neel Lahoti CEO, Synergen Bio Pvt. Ltd., Pune, Maharashtra, India
  • Vinayak Bhosale Senior Research Operator, Synergen Bio Pvt. Ltd., Pune, Maharashtra, India
  • Arif Khan Senior Manager, Synergen Bio Pvt. Ltd., Pune, Maharashtra, India
  • Rishikesh Yadav Research Associate, Synergen Bio Pvt. Ltd., Pune, Maharashtra, India.
  • Snehal Patil Research Associate-I , Bioanalytical Research, Synergen Bio Pvt. Ltd., Pune, Maharashtra, India

Keywords:

Penfluridol, LC-MS/MS, Antipsychotic, Depot Drug, K2EDTA

Abstract

Penfluridol is a new long-acting neuroleptic drug known to be used widely for treating psychotic conditions. An internal standard was employed, which was penfluridol D7 (IS). The analyte and the IS were separated on a Phenomenex Kinetex C18, 5µm 100A, 100*4.6mm column using acetonitrile (40:60, v/v) as the mobile phase and 5 mM ammonium formate as the stationary phase. The retention time of Penfluridol and Penfluridol d7 was set at 2.94 and 2.75 mins respectively. Penfluridol and Penfluridol-d7 were detected and measured using the precursor to product ion transitions of m/z 524.300/203.100 m/z and 531.400/204.100 m/z, respectively. The investigation made use of an API-6500+ LC-MS/MS system running in multiple reactions monitoring (MRM) mode and outfitted with a turbo ion spray (TIS) source.We developed a highly sensitive, selective, and precise method for quantification of Penfluridol in human plasma.

References

Van Praag HM, Schut T, Dols L, Van Schilfgaarden R. Controlled trial of penfluridol in acute psychosis. Br Med J. 1971 Dec 18;4(5789):710-3.

Janssen PA, Niemegeers CJ, Schellekens KH, Lenaerts FM, Verbruggen FJ, Van Nueten JM, Marsboom RH, Herin VV, Schaper WK. The pharmacology of fluspirilene (R 6218), a potent, long-acting and injectable neuroleptic drug. Arzneimittel-forschung. 1970 Nov;20(11):1689-98.

Cooper SF, Albert JM. Gas-Liquid Chromatographie Determination of Penfluridol in Plasma. International Pharmacopsychiatry. 1975;10:78-88.

Iversen L, editor. Handbook of Psychopharmacology: Volume 10: Neoroleptics and Schizophrenia. Springer Science & Business Media; 2012 Dec 6.

Airoldi L, Marcucci F, Mussini E, Garattini S. Distribution of penfluridol in rats and mice. European Journal of Pharmacology. 1974 Mar 1;25(3):291-5.

Baro F, Brugmans J, Dom R, Van Lommel R. Maintenance Therapy of Chronic Psychotic Patients with a Weekly Oral Dose of R16 341. A Controlled Double‐Blind Study. The Journal of Clinical Pharmacology and The Journal of New Drugs. 1970 Sep 10;10(5):330-41.

De Wied D, Sigling HO. Neuropeptides involved in the pathophysiology of schizophrenia and major depression. Neurotoxicity research. 2002 Jan 1;4(5-6):453-68.

Haase HJ, Fischer D, Floru L, Frank T, Joseph K, Knaack M, Mohr W, Richter-Peill H, Steuer A, Wahl G, Walterbusch G. Long term neuroleptic therapy using fluspirilene and penfluridol. Der Nervenarzt. 1971 Dec;42(12):632-7.

Möller HJ, Kissling W, Kockott G, Wittmann D. Depot-neuroleptics in acute psychiatry. InPsychiatry the State of the Art 1985 (pp. 763-769). Springer, Boston, MA.

J. Melon, “[Two cases of erotomania treated with penfluridol (R16341)].,” Acta Psychiatr. Belg., 1971 Sep;11(5):414-25.

Ota KY, Kurland AA, Slotnick VB. Safety evaluation of penfluridol, a new long-acting oral antipsychotic agent. Journal of Clinical Pharmacology. 1974 Apr.

Gallant DM, Mielke DH, Spirtes MA, Swanson WC, Bost R. Penfluridol: an efficacious long-acting oral antipsychotic compound. American Journal of Psychiatry. 1974 Jun;131(6):699-702.

Party EW, Committee for Medicinal Products for Human Use. Committee for Medicinal Products for Human Use (CHMP) guideline on Data Monitoring Committees. Statistics in medicine. 2006 May 30;25(10):1639-45.

Fda and Cder, “Bioanalytical Method Validation Guidance for Industry Biopharmaceutics Bioanalytical Method Validation Guidance for Industry Biopharmaceutics Contains Nonbinding Recommendations,” 2018, Accessed: Jul. 09, 2021. [Online]. Available: https://www.fda.gov/

files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf

Downloads

Published

2022-08-29

Issue

Vol. 9 No. 2 (2022)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.